Guggenheim Capital LLC Sells 23,976 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Guggenheim Capital LLC reduced its stake in Intuitive Surgical by 23.9%, selling 23,976 shares, leaving them with 76,300 shares valued at approximately $37.79 million.
• Multiple institutional investors have modified their holdings in Intuitive Surgical, with notable increases from Castleark Management LLC (+3.4%) and Longbow Finance SA (+132.0%).
• Analysts remain positive on Intuitive Surgical, with 13 “Buy” ratings and an average price target of $595.95 following recent earnings that exceeded expectations.

Guggenheim Capital LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 23.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 76,300 shares of the medical equipment provider's stock after selling 23,976 shares during the period. Guggenheim Capital LLC's holdings in Intuitive Surgical were worth $37,789,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Castleark Management LLC boosted its holdings in shares of Intuitive Surgical by 3.4% during the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock worth $47,221,000 after buying an additional 2,990 shares in the last quarter. Arlington Trust Co LLC grew its position in Intuitive Surgical by 34.5% in the 1st quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after purchasing an additional 191 shares during the period. Aveo Capital Partners LLC grew its position in Intuitive Surgical by 37.4% in the 1st quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 198 shares during the period. Aaron Wealth Advisors LLC grew its position in Intuitive Surgical by 3.2% in the 1st quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock valued at $1,243,000 after purchasing an additional 78 shares during the period. Finally, Longbow Finance SA grew its position in Intuitive Surgical by 132.0% in the 1st quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider's stock valued at $9,756,000 after purchasing an additional 11,209 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Gary S. Guthart sold 2,800 shares of Intuitive Surgical stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the sale, the insider owned 18,520 shares of the company's stock, valued at approximately $9,171,844.80. This trade represents a 13.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares of the company's stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,839 shares of company stock valued at $7,896,972. 0.70% of the stock is owned by insiders.

Analyst Ratings Changes

ISRG has been the subject of several research reports. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. Citigroup reissued a "buy" rating and issued a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Royal Bank Of Canada reissued an "outperform" rating and issued a $615.00 price target on shares of Intuitive Surgical in a research report on Tuesday, August 19th. Piper Sandler reissued an "overweight" rating and issued a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Finally, Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Thirteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $474.26 on Wednesday. The stock has a market capitalization of $170.01 billion, a price-to-earnings ratio of 66.15, a PEG ratio of 4.91 and a beta of 1.59. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The business's fifty day moving average is $502.65 and its 200-day moving average is $520.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter last year, the firm posted $1.78 EPS. The firm's revenue for the quarter was up 21.4% on a year-over-year basis. Research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.